UBS has revised its price target for DocMorris, lowering it to 25 francs, while maintaining a "Sell" rating.
Concerns have been raised by analyst Sebastian Vogel about the online pharmacy's growth prospects in the German prescription drug market, indicating a weaker business outlook in the short term.
The report, published on October 16, 2024, reflects UBS's assessment of the current market conditions affecting DocMorris.
The stock's performance has been closely monitored, with recent trading data showing fluctuations in its value.